drugset / Trial / NCT00606632

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

NCT00606632

Phase 3 Completed 226 enrolled Heidelberg Pharma AG
NaSingle-groupOpen-labelDiagnostic

Summary

This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.

Timeline

Start
2008-03
Primary completion
2009-11
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject girentuximab Monoclonal antibody Intravenous

Indications